(Q38733038)

English

Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.

scientific article published on 3 November 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Giuseppe Catapano

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

author name string

Elena Ciaglia

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Chiara Laezza

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Simona Pisanti

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Mario Vitale

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Vincenzo Seneca

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Giovanni Torelli

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Silvia Franceschelli

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Patrizia Gazzerro

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Maurizio Bifulco

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

language of work or name

0 references

publication date

16 November 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

International Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

140

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

959-972

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

The WHO classification of tumors of the nervous system

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Glioblastoma in adults

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

The EGFRvIII variant in glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Regulation of receptor tyrosine kinase signaling by endocytic trafficking

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Escape from targeted inhibition: the dark side of kinase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Involvement of Akt/NF-κB pathway in N6-isopentenyladenosine-induced apoptosis in human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

N6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

N6-isopentenyladenosine: a potential therapeutic agent for a variety of epithelial cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Epidermal growth factor receptors: critical mediators of multiple receptor pathways

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Threshold-controlled ubiquitination of the EGFR directs receptor fate

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma multiforme through de-repression of Bcl-xL translation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

ATF3 and Fra1 have opposite functions in JNK- and ERK-dependent DNA damage responses.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Signal transduction by receptors with tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

CYTOKININ METABOLISM AND ACTION.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

rab7 activity affects epidermal growth factor:epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Biological and pharmacological roles of N6-isopentenyladenosine: an emerging anticancer drug

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30505

21 January 2018

Identifiers

10.1002/IJC.30505

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27813087%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38733038&oldid=1506515900"